



Systematic Review Effectiveness of Time-Restricted Eating with Caloric Restriction vs. Caloric Restriction for Weight Loss and Health: Meta-Analysis

Tanja Črešnovar[†], Bernarda Habe[†], Zala Jenko Pražnikar 💿 and Ana Petelin *💿

Faculty of Health Sciences, University of Primorska, Polje 42, 6310 Izola, Slovenia; tanja.cresnovar@fvz.upr.si (T.Č.); bernarda.habe@fvz.upr.si (B.H.); zala.praznikar@fvz.upr.si (Z.J.P.)

* Correspondence: ana.petelin@fvz.upr.si; Tel.: +386-05-662-6469

⁺ These authors have contributed equally to this work.

Abstract: Time-restricted eating (TRE) is an increasingly popular dietary strategy for weight loss. Recent studies suggest that combining TRE with caloric restriction (CR) may have more favorable effects on both physical and biochemical aspects when compared with CR alone. Therefore, we performed a meta-analysis to compare the effects of TRE with CR vs. CR alone on anthropometric and biochemical measures in overweight or obese adults. We reviewed articles from PubMed, Web of science, EMBASE, and the Cochrane Library published before 25 May 2023. The meta-analysis incorporated data from seven randomized controlled trials of nine interventions, with a total of 231 participants in the TRE with CR group and 227 participants in the CR-only group. Data were analyzed using RewMan version 5.4.1. All results in our meta-analysis were described as mean difference (MD) with 95% confidence interval (Cl). Results showed that TRE with CR compared to CR alone resulted in significantly greater reductions in body weight (MD: -2.11 kg, 95% CI: -2.68 kg to -1.54 kg, $p = \langle 0.00001, I^2 = 42\% \rangle$, body fat mass (MD: -0.75 kg, 95% CI: -1.35 kg to -0.16 kg, $p = 0.01; I^2 = 0\% \rangle$, and waist circumference (MD: -1.27 cm, 95% CI: -2.36 cm to -0.19 cm, p = 0.02, $l^2 = 0\%$), while no additional impact of TRE in combination with CR in comparison to CR on serum biochemical parameters were found. Our results suggest that the improvement in biochemical parameters are mainly caused by CR, while improvements in anthropometric parameters are further enhanced by TRE.

Keywords: time-restricted eating; caloric restriction; overweight; obesity; weight loss; lipid profile; fasting glucose

1. Introduction

Obesity is a complex health condition characterized by excessive accumulation of body fat due to a combination of genetic, environmental, and behavioral factors. Obesity increases the risk of several chronic diseases, including type 2 diabetes mellitus, cardio-vascular disease, kidney and liver disease, and certain types of cancers [1]. In addition, recent data show that obesity and impaired metabolism are important risk factors for severe coronavirus disease (COVID-19) [2]. It also affects overall quality of life and can lead to psychological and social consequences [3]. The prevalence of obesity is increasing worldwide and represents a major public health challenge [4].

There are several strategies for weight loss and weight loss maintenance that vary in macronutrient composition and degree of caloric restriction (CR). Nevertheless, effective strategies to achieve weight loss and long-term weight loss maintenance have proved to be elusive. Optimal diets and exercise plans for weight loss are a topic of debate among researchers, nutrition experts, and the general public. CR is the most important factor and is traditionally recommended in weight loss or weight-management strategies [5]. In



Citation: Črešnovar, T.; Habe, B.; Jenko Pražnikar, Z.; Petelin, A. Effectiveness of Time-Restricted Eating with Caloric Restriction vs. Caloric Restriction for Weight Loss and Health: Meta-Analysis. *Nutrients* **2023**, *15*, 4911. https://doi.org/ 10.3390/nu15234911

Academic Editor: Maria Luz Fernandez

Received: 17 October 2023 Revised: 13 November 2023 Accepted: 21 November 2023 Published: 24 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). recent years, time-restricted eating (TRE) has gained scientific and public attention as an alternative to conventional weight loss strategies [6].

TRE is an eating pattern in which the daily eating window is limited to a specific period of time, usually between 4 and 12 h, with fasting during the remaining hours. TRE differs from other forms of intermittent fasting in that it requires a consistent time of the daily eating window. It aims to align the body's natural circadian rhythms with the eating schedule [7].

TRE has been shown to have positive effects in humans; it leads to weight loss, increases insulin sensitivity, lowers blood pressure, and has other positive effects on metabolic health [8]. In humans, however, TRE, when practiced under ad libitum conditions, often leads to an unintended reduction in energy intake, which in turn may lead to weight loss and various cardio-metabolic benefits such as improved insulin sensitivity and lower blood pressure. However, it remains uncertain whether these beneficial effects observed in humans are primarily attributed to the unintentional CR that results from fasting alone, or whether they are due to a combination of both factors [7].

Previous studies have also shown that the effects of TRE may depend on the timing of food intake, but the exact timing has not been well defined. It is not yet clear whether differences occur when food intake is restricted to the early or late part of the day [8]. Another interesting unanswered question is whether the efficacy of a caloric restrictive diet is improved by the implementation of a TRE. Some research questions remain unresolved because of the large heterogeneity of studies. Therefore, the main objective of the present systematic meta-analysis, which considers homogeneous and recent research in the field, is to evaluate the health effects of TRE with CR vs. CR. In addition, we aim to perform subgroup analyses of eTRE, ITRE, and mTRE with CR vs. CR to determine which subgroup of TRE with CR is most effective regarding anthropometric and biochemical parameters. This is indeed a new, unexplored, and very interesting topic for research, and for this reason we would like to highlight where further high quality studies are still needed.

2. Materials and Methods

2.1. Search Strategy

The search strategy was based on keywords. Medical subject headings (MeSH), title/abstract keywords, and free-text search terms were used. Databases searched included PubMed, Web of Science, Cochrane Library, and EMBASE from 20 April 2023 to 25 May 2023. Moreover, grey literature was searched via Greylit and OpenGrey. Search terms included combinations of »time restricted eating«, or »time restricted feeding«, or »time restricted diet« and »calorie restriction«, or »caloric restriction«, or »energy restriction«, or »energy restriction«, or »overweight«, or »obesity«. The detailed search strategy for each database is presented in Appendix A. Search criteria were research papers no older than ten years and randomized trials, available in full text and written in English.

This meta-analysis was registered with the International Prospective Register of Systematic Reviews (PROSPERO) database (registration ID: CRD42023478917). The literature search was conducted according to the recommended protocol of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and the checklist [9]. All titles and abstracts were screened for eligibility by two independent reviewers (T.Č. and B.H.). Figure 1 shows the detailed search strategy.



Figure 1. PRISMA flow diagram.

From all identified records, 3659 duplicate records were removed. After removing the duplicate records, 7733 titles and abstracts were checked. In addition, 45 full texts were screened using our criteria. A total of 38 studies were excluded because they did not meet our inclusion criteria. Finally, 7 studies were considered for data extraction and analysis (Figure 1). When searching the grey literature, we found no further studies relevant to our analysis.

2.2. Study Selection

Eligibility criteria were defined using the PICO framework (Population, Intervention, Comparator, Outcome) [10]. We included studies with the following characteristics: (1) Population: adults aged 18 years or older, with or without metabolic syndrome, and with a BMI > 25 kg/m². (2) Intervention: a daily fasting period with 14–18 h fasting and 6–10 eating windows with CR or a low-carbohydrate diet, two to four months duration. (3) Comparators: a control group in randomized control trials (RCTs) with CR or a lowcarbohydrate diet. (4) We divided TRE with CR regimes into: early time-restricted eating (eTRE) with CR, late time-restricted eating (ITRE) with CR, and mTRE with undefined beginning of TRE (eTRE or ITRE) with CR. Specifically, the food intake of eTRE started before 11:00 AM, and the food intake of ITRE started at 11:00 AM or later. (5) Outcomes: data on changes in at least one of the following: body weight (BW), fat-free mass (FFM), fat mass (FM), waist circumference (WC), diastolic blood pressure (DBP), systolic blood pressure (SBP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglycerides (TG), or fasting glucose (FG). (6) Due to the small number of studies comparing eTRE with ITRE, we also included a study with a low-carbohydrate diet [11] in which energy intake was not monitored, but we assume that spontaneous CR occurred.

We excluded studies with the following characteristics: (1) an intervention or a control group without CR or a low-carbohydrate diet; (2) studies including participants with acute or chronic diseases, such as gastrointestinal diseases, liver/kidney diseases or cancer, type 2 diabetes mellitus, or cardiovascular diseases that affect the outcomes; (3) studies including athletes or participants with intensity physical activity; and (4) animal experiments, meta-analyses, case reports, reviews, conference abstracts, and protocols.

2.3. Data Extraction and Collection

Based on the inclusion and exclusion criteria, two authors independently extracted studies into the database (Mendeley Reference Manager). If necessary, a third researcher was consulted. For data that were not available in the articles, we attempted to contact the authors of the articles to obtain information about the missing data. We used Microsoft Excel 2021 to create a table in which all important data from the included studies were entered. The following variables were extracted from each study by these investigators using the same criteria: author's name, publication year, study group, study duration, outcomes measured, type of intervention, eating window, CR, sample size, and participant characteristics (sex, age, BMI) (Table 1).

Study	Country	Study Group (Population)	Duration	Outcomes	Type of Intervention	Eating Window	Caloric Restriction (CR)	Sample Size n (m/f)	Age (Years)	BMI (kg/m²)
Queiroz et al. (2023)	Brozil	Overweight and	8 wooks	Changes in BW, FFM, FM,	eTRE	(8:16) 8:00–16:00	-25% EI	13 (2/11)	33 ± 6	30.0 ± 8.0
[7]	Drazii	obesity	o weeks	HDL, LDL, TG, TC, FG	ITRE	(8:16) 12:00–20:00	-25% EI	11 (2/9)	30 ± 7	30.0 ± 5.0
					Non-TRE	8:00-20:00	-25% EI	13 (2/11)	26 ± 4	30.0 ± 1.0
Thomas et al. (2022) [12]	Colorado, USA	Overweight and obesity	12 weeks	Changes in BW, FFM, FM	eTRE	Starting within 3 h after waking up	-35% EI	41 (7/34)	38 ± 8	34.6 ± 5.8
					Non-TRE	Unrestricted eating time	-35% EI	40 (5/35)	38 ± 8	33.7 ± 5.6
Steger et al. (2023)	United Kingdom	Obesity	14 weeks	Changes in BW, FFM, FM	eTRE	(8:16) 7:00–15:00	-500 kcal/day	15 (4/11)	46 ± 11	38.5 ± 7.1
[13]	0	,		0 , ,	Non-TRE	$\geq 12 \text{ h/day}$	-500 kcal/day	21 (6/15)	42 ± 12	38.3 ± 6.0
Lin et al. (2022) [14]	Taiwan	Normal and overweight	8 weeks	Changes in BW, FFM, WC, DBP, SBP, HDL, LDL, TG,	mTRE	10:00–18:00 or 12:00–20:00	-200 kcal/day	30 (0/30)	50 ± 8	25.9 ± 3.7
		women		TC, FG	Non-TRE	Unrestricted eating time	-200 kcal/day	33 (0/33)	54 ± 8	25.7 ± 3.8
He et al. (2022) [11]	China	Obesity with metabolic syndrome	12 weeks	Changes in BW, FM, WC, DBP, SBP	eTRE	(8:16) 8:00–16:00	Carbohydrate restriction to < 26% of EI; CR undefined Carbohydrate	32 (22/10)	41 ± 9	29.1 ± 3.4
					ITRE	(8:16) 12:00–20:00	restriction to < 26% of EI; CR undefined	20 (15/5)	37 ± 8	28.8 ± 2.7
					Non-TRE	Unrestricted eating time	Carbohydrate restriction to < 26% of EI; CR undefined	55 (30/25)	41 ± 1	29.3 ± 3.7
Kunduraci et al. (2020) [15]	Turkey	Obesity with metabolic syndrome	12 weeks	Changes in BW, FFM, FM, WC, DBP, SBP, HDL, LDL, TG, TC, FG	mTRE	(8:16) 8:00–16:00 or 9:00–17:00 or 10:00–18:00 or 11:00–19:00 Unrestricted	-25% EI	32 (16/16)	47 ± 12 49 ± 12	36.6 ± 5.3
					INOII-I KE	eating time (8:16)	-23 /0 EI	33 (13/18)	49 ± 12	52.7 ± 4.1
Jamshed et al. (2022) [16]	Alabama, USA	Obesity	12 weeks	Changes in BW, FFM, FM, WC, DBP, SBP, HDL, LDL,	eTRE	7:00–15:00	-500 kcal/day	45 (10/35)	43 ± 10	40.1 ± 6.6
[-0]				TG, TC, FG	Non-TRE	\geq 12 h/day	−500 kcal/day	45 (8/37)	43 ± 11	39.2 ± 6.8

Data are presented as mean \pm SD. Abbreviations: BW, body weight; CR, caloric restricition; DBP, diastolic blood pressure; FG, fasting glucose; f, female; HDL, high-density lipoprotein cholesterol; EI, energy intake; eTRE, early time-restricted eating; FFM, fat-free mass; FM, fat mass; ITRE, late time-restricted eating; LDL, low-density lipoprotein cholesterol; m, male; mTRE, undifined beginning of time-restricted eating; non-TRE, without time-restricted eating; SBP, systolic blood pressure; TC, total cholesterol; TG, total triglycerides; USA, United States of America; WC, waist circumference.

2.4. Risk of Bias and Certainty of Evidence Assessment

The quality assessment of included studies is shown in Figure 2. The Cochrane Collaboration's tool was used to assess the risk of bias in studies [17]. The risk of bias was assessed by two independent reviewers (T.Č. and B.H.). Bias was assessed as a judgement (high, low, or unclear) for six elements: (1) random sequence generation (selection bias); (2) allocation concealment (selection bias); (3) blinding of outcome assessment (detection bias); (4) incomplete outcome data (attrition bias); (5) selective reporting (reporting bias); and (6) other bias. One study was categorized as having a high risk of incomplete outcome data because the measurements were conducted by participants at home [12], and one study because participants were not randomly assigned to eTRE or ITRE [11]. Another study had three unclear risks of bias, because there was no description of the randomization, allocation, and blinding of outcome process [14] (Figure 2).



Figure 2. Risk of bias assessment in the RCT s included in the meta-analysis. Criteria for each included RCTs according to Cochrane Risk-of-Bias tool. Abbreviations: –, low risk [7]; ?, unclear risk [13–16]; +, high risk [11,12] in the PRISMA flow diagram.

We assessed the certainty of the evidence of each outcome using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework [18] (Table 2). The GRADE framework was used was to categorize the quality of evidence of each outcome as very low, low, moderate, and high level by two independent researchers (T.Č. and H.B.). The RCT studies were classified as high quality initially and then downgraded or upgraded depending on predefined criteria, including the risk of bias, consistency, indirectness, and imprecision of results.

Table 2. Certainty of the evidence.

			Certainty Assessmen	ıt			No. of Pat	ients		Effect	
No. of Studies	Study Design	Risk of Bias	Inconsistency	Indirectness	Imprecision	Other Considerations	TRE with CR	CR	Relative (95% CI)	Absolute (95% CI)	Certainty
						3W					
9	randomized trials	serious	not serious	not serious	serious	none	231	295	-	MD 2.11 lower (2.68 lower to 1.54 lower)	Low
						BM					
8	randomized trials	serious	not serious	not serious	serious	none	192	258	-	MD 0.75 lower (1.35 lower to 0.16 lower)	Low
					I	FM					
7	randomized trials	serious	not serious	not serious	serious	none	170	181	-	MD 0.22 lower (0.68 lower to 0.25 higher)	Low
					,	WC					
5	randomized trials	serious	not serious	not serious	serious	none	165	221	-	MD 1.27 lower (2.36 lower to 0.19 lower)	Low
						SBP					
5	randomized trials	serious	serious	not serious	serious	none	159	221	-	MD 0.36 lower (4.56 lower to 3.84 higher)	Very low
					I	DBP					
5	randomized trials	serious	very serious	not serious	serious	none	159	221	-	MD 2.42 lower (7.6 lower to 2.77 higher)	Very low
						FG					
4	randomized trials	serious	not serious	not serious	serious	none	131	137	-	MD 0.14 higher (0.87 lower to 1.15 higher)	Low
						TC					
5	randomized trials	serious	not serious	not serious	serious	none	131	137	-	MD 0.98 higher (2.19 lower to 4.15 higher)	Low
					Η	IDL					
5	randomized trials	serious	not serious	not serious	serious	none	131	137	-	MD 1.71 higher (0.22 lower to 3.65 higher)	Low
					I	.DL					
5	randomized trials	serious	not serious	not serious	serious	none	131	137	-	MD 0.77 higher (2.59 lower to 1.05 higher)	Low
						TG					
5	randomized trials	serious	not serious	not serious	serious	none	131	137	-	MD 2.26 higher (4.43 lower to 8.96 higher)	Low

Abbreviations: BW, body weight; CR, caloric restricition; DBP, diastolic blood pressure; FG, fasting glucose; HDL, high-density lipoprotein cholesterol; FFM, fat-free mass; FM, fat mass; LDL, low-density lipoprotein cholesterol; MD, mean difference; SBP, systolic blood pressure; TC, total cholesterol; TG, total triglycerides; TRE, time-restricted eating; WC, waist circumference.

2.5. Data Analysis and Statistical Methods

Data were analyzed, and forest plots were produced using RewMan version 5.4.1. All results were expressed as mean differences (MDs) with standard deviations (SDs) and/or their 95% confidence intervals (CIs). If the SD of outcomes' indicators were not available, SDs were calculated using standard errors or confidence intervals for group means based on the approach described in the Cochrane Handbook for Systematic Reviews of intervention [19]. We assumed a correlation of 0.75 from baseline to follow-up measurements to calculate missing values. I^2 was used to represent the heterogeneity of the results (0 to 40% for possibly not significant; 30 to 60% for may indicate moderate heterogeneity; 50 to 90% for may indicate significant heterogeneity; 75 to 100% for significant heterogeneity). Therefore, the random-effect model was [7,11–16] used if $I^2 > 50\%$; otherwise, the fixed-effect model was used. p < 0.05 was considered statistically significant. We used a random-effect model when the set of studies was heterogeneous and inconsistent ($I^2 > 50\%$), because the random-effect meta-analysis gave the studies proportionally more weight than they would have received in a fixed-effect meta-analysis. A fixed-effect model was used when $I^2 < 50\%$, which meant that studies with low heterogeneity were pooled in the meta-analysis.

3. Results

3.1. Effects of TRE with CR vs. CR on Changes in Anthropometric Parameters

Seven studies were compared. Two different interventions (eTRE and ITRE) were implemented in two studies.

Changes in BW were measured in all nine interventions [7,11–16] including 231 participants in the TRE group with CR and 227 participants in the control group with CR. The MD of BW change between groups using a fixed-effect model was -2.11 kg (95% CI: -2.68 kg to -1.54 kg, p = < 0.00001, $l^2 = 42\%$) (Figure 3), indicating a significantly greater BW loss in the TRE with CR group compared with the CR group. Both, eTRE and ITRE subgroups with CR, compared to the control group with CR resulted in a significantly greater BW loss. The random-effect model (Figure 4) for eTRE [7,11–13,16] showed an additional loss of -2.19 kg BW compared to CR (95% CI: -3.42 kg to -0.96 kg; p < 0.0005, $l^2 = 59\%$) and the fixed-effect model for ITRE showed an additional loss of -1.43 kg BW compared to CR (95% CI: -2.52 kg to -0.35 kg, p = 0.01, $l^2 = 15\%$) [7,11]. In addition, the mTRE subgroup also showed a significant additional BW reduction of -2.08 kg compared to CR (95% CI: -3.80 kg to -0.36 kg, p = 0.02, $l^2 = 0\%$) (Figure 3) [14,15].

	Exp	eriment	al	Control				Mean difference	Mean difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
1.1.1 eTRE with CR										
He et al., 2022	-5.6	2.83	32	-2.2	2.22	55	25.1%	-3.40 [-4.54 , -2.26]	-	
Jamshed et al., 2022	-6.3	3.66	45	-4	3.66	45	14.4%	-2.30 [-3.81 , -0.79]		
Queiroz et al., 2023	-4.2	2.4	13	-4	3.14	13	7.1%	-0.20 [-2.35 , 1.95]		
Steger et al., 2023	-7.6	3.87	15	-3.9	4.12	21	4.7%	-3.70 [-6.33 , -1.07]		
Thomas et al., 2022	-6.2	4.1	33	-5.1	3.2	27	9.6%	-1.10 [-2.95 , 0.75]		
Subtotal (95% CI)			138			161	60.9%	-2.43 [-3.16 , -1.69]	•	
Heterogeneity: Chi ² = 9	.82, df = 4 (P = 0.04	; l ² = 59%	5						
Test for overall effect: Z	= 6.48 (P	< 0.00001)							
1.1.2 ITRE with CR										
He et al., 2022	-4.2	3.13	20	-2.2	2.22	55	14.7%	-2.00 [-3.49 , -0.51]	_	
Queiroz et al., 2023	-4.8	1.97	11	-4	1.95	13	13.2%	-0.80 [-2.37 , 0.77]		
Subtotal (95% CI)			31			68	28.0%	-1.43 [-2.52 , -0.35]	•	
Heterogeneity: Chi ² = 1	.18, df = 1 (P = 0.28): l ² = 15%	5						
Test for overall effect: Z	= 2.59 (P =	= 0.010)								
1.1.3 mTRE with CR										
Kunduraci et al., 2020	-8.27	4.58	32	-5.8	3.73	33	7.9%	-2.47 [-4.50 , -0.44]		
Lin et al., 2022	-2.7	6.89	30	-1.6	6.12	33	3.1%	-1.10 [-4.33 , 2.13]		
Subtotal (95% CI)			62			66	11.1%	-2.08 [-3.80 , -0.36]	•	
Heterogeneity: Chi ² = 0	.49, df = 1 (P = 0.48	$ 1^2 = 0\%$						· ·	
Test for overall effect: Z	= 2.37 (P =	= 0.02)								
Total (95% CI)			231			295	100.0%	-2.11 [-2.68 , -1.54]		
Heterogeneity: Chi ² = 1	3.72, df = 8	(P = 0.09)	9); I ² = 42	%						
Test for overall effect: Z	= 7.22 (P	< 0.00001)					-10	-5 0 5	
Test for subaroup differ	ences: Chi ²	= 2.23. d	f = 2 (P =	0.33), ² =	10.2%			TRE with CR [e	xperimental] CR [control	

Figure 3. Effect of TRE with CR vs. CR on changes in BW (in kg). Interventions divided into subgroups (eTRE, ITRE, mTRE). MD indicates the mean difference of change from TRE with CR vs. CR. The plotted

points are the MDs, and the horizontal error bars represent the 95% confidence intervals. Abbreviations: CR, caloric restriction; eTRE, early time-restricted eating; ITRE, late time-restricted eating; TRE, time-restricted eating; mTRE, undefined beginning of time-restricted eating. The diamond at the base of the plot demonstrates the pooled effect estimates and confidence intervals from all RCTs included in the meta-analysis [7,11–16].

	Exp	erimenta	al		Control			Mean difference	Mean differen	ce
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95%	% CI
He et al., 2022	-5.6	2.83	32	-2.2	2.22	55	27.0%	-3.40 [-4.54 , -2.26]	4	~~
Jamshed et al., 2022	-6.3	3.65	45	-4	3.66	45	23.0%	-2.30 [-3.81 , -0.79]		
Queiroz et al., 2023	-4.2	2.4	13	-4	3.14	13	17.0%	-0.20 [-2.35 , 1.95]		
Steger et al., 2023	-7.6	3.87	15	-3.9	4.12	21	13.5%	-3.70 [-6.33 , -1.07]		
Thomas et al., 2022	-6.2	4.1	33	-5.1	3.2	27	19.6%	-1.10 [-2.95 , 0.75]		
Total (95% CI)			138			161	100.0%	-2.19 [-3.42 , -0.96]	•	
Heterogeneity: Tau ² =	1.12; Chi ² =	9.82, df	= 4 (P = 0	0.04); ² = 5	59%				•	
Test for overall effect: 2	Z = 3.50 (P	= 0.0005)						-10 -5 0	5 10
Test for subgroup differ	le					eTRE with CF	R [experimental] CR	[control]		

Figure 4. Random effect of TRE with CR vs. CR on changes in BW (in kg). MD indicates the mean difference of change from eTRE with CR vs. CR. The plotted points are the MDs, and the horizontal error bars represent the 95% confidence intervals. Abbreviations: CR, caloric restriction; eTRE, early time-restricted eating. The diamond at the base of the plot demonstrates the pooled effect estimates and confidence intervals from all RCTs included in the meta-analysis [7,11–13,16].

Changes in FM were evaluated across eight interventions [7,11–13,15,16], encompassing 192 participants in the TRE with CR group and 190 in the CR group. Overall, the TRE with CR group exhibited a significantly greater reduction in FM than the control group with CR (MD: -0.75 kg, 95% CI: -1.35 kg to -0.16 kg, p = 0.01; $I^2 = 0\%$) (Figure 5a).

	Exp	perimenta	al		Control			Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.3.1 eTRE with CR									
He et al., 2022	-2.8	4.53	32	-2	2.97	55	11.6%	-0.80 [-2.55 , 0.95]	
Jamshed et al., 2022	-4.7	2.66	45	-3.4	3.99	45	18.1%	-1.30 [-2.70, 0.10]	
Queiroz et al., 2023	-2.9	1.97	13	-3.1	1.95	13	15.7%	0.20 [-1.31 , 1.71]	-
Steger et al., 2023	-2.8	10.84	15	-1.6	7.33	21	0.9%	-1.20 [-7.52 , 5.12]	
Thomas et al., 2022	-2.8	1.8	24	-2.1	2.6	23	21.6%	-0.70 [-1.98 , 0.58]	
Subtotal (95% CI)			129			157	67.9%	-0.68 [-1.40 , 0.05]	٠
Heterogeneity: Chi ² = 2	.11, df = 4 (P = 0.72)	; l ² = 0%						
Test for overall effect: Z	= 1.83 (P =	= 0.07)							
1.3.2 ITRE with CR									
He et al., 2022	-3.2	3.13	20	-2	2.97	55	14.3%	-1.20 [-2.78, 0.38]	
Queiroz et al., 2023	-3.6	1.97	11	-3.1	1.95	13	14.4%	-0.50 [-2.07 , 1.07]	
Subtotal (95% CI)			31			68	28.6%	-0.85 [-1.96 , 0.27]	•
Heterogeneity: Chi ² = 0	.38, df = 1 ((P = 0.54)	; l ² = 0%						•
Test for overall effect: Z	= 1.49 (P =	= 0.14)							
1.3.3 mTRE with CR									
Kunduraci et al., 2020	-5.52	6.87	32	-4.09	6.24	33	3.5%	-1.43 [-4.62 , 1.76]	
Subtotal (95% CI)			32			33	3.5%	-1.43 [-4.62 , 1.76]	
Heterogeneity: Not app	licable								
Test for overall effect: Z	= 0.88 (P =	= 0.38)							
Total (95% CI)			192			258	100.0%	-0.75 [-1.35 , -0.16]	•
Heterogeneity: Chi ² = 2	.73, df = 7 ((P = 0.91)); l ² = 0%						•
Test for overall effect: Z	= 2.47 (P =	= 0.01)						-10	-5 0 5 10
Test for subgroup different	ences: Chi ²	= 0.24, d	lf = 2 (P =	= 0.89), l² =	0%			TRE with CR [ex	(perimental] CR [control]
						(a)			

Figure 5. Cont.

	Exp	perimenta	al		Control			Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.4.1 eTRE with CR									
He et al., 2022	-1.3	1.98	45	-1.5	1.98	45	32.4%	0.20 [-0.62 , 1.02]	-
Queiroz et al., 2023	-1.2	1.97	13	-1	1.95	13	9.5%	-0.20 [-1.71 , 1.31]	
Steger et al., 2023	-1.8	2.32	15	-1.2	1.37	21	12.6%	-0.60 [-1.91, 0.71]	
Thomas et al., 2022	-1.5	1.4	24	-1.1	1.8	23	25.3%	-0.40 [-1.32 , 0.52]	_
Subtotal (95% CI)			97			102	79.8%	-0.16 [-0.69 , 0.36]	•
Heterogeneity: Chi ² = 1.	.44, df = 3 (P = 0.70)	$ ^2 = 0\%$						1
Test for overall effect: Z	= 0.62 (P =	= 0.54)							
1.4.2 ITRE with CR									
Queiroz et al., 2023	-1.2	1.97	11	-1	1.95	13	8.7%	-0.20 [-1.77 , 1.37]	
Subtotal (95% CI)			11			13	8.7%	-0.20 [-1.77 , 1.37]	•
Heterogeneity: Not appl	icable								T
Test for overall effect: Z	= 0.25 (P =	= 0.80)							
1.4.3 mTRE with CR									
Kunduraci et al., 2020	-2.75	7.31	32	-1.71	6.2	33	2.0%	-1.04 [-4.34 , 2.26]	
Lin et al., 2022	-0.7	3.18	30	-0.2	2.92	33	9.5%	-0.50 [-2.01 , 1.01]	
Subtotal (95% CI)			62			66	11.5%	-0.59 [-1.97, 0.78]	•
Heterogeneity: Chi ² = 0.	.09, df = 1 (P = 0.77)	; l ² = 0%						
Test for overall effect: Z	= 0.85 (P =	= 0.40)							
Total (95% CI)			170			181	100.0%	-0.22 [-0.68 , 0.25]	4
Heterogeneity: Chi ² = 1.	.85, df = 6 (P = 0.93)	; l ² = 0%						
Test for overall effect: Z	= 0.91 (P =	= 0.36)						-10	-5 0 5
Test for subgroup differe	ences: Chi ²	= 0.33, d	f = 2 (P =	0.85), l ² =	0%			TRE with CR [e:	xperimental] CR [control]
						(b)			

Figure 5. Effect of TRE with CR vs. CR on changes in (**a**) FM (in kg) and (**b**) FFM (in kg). Interventions were divided into subgroups (eTRE, ITRE, mTRE). MD indicates the mean difference of change from TRE with CR vs. CR. The plotted points are the MDs, and the horizontal error bars represent the 95% confidence intervals. Abbreviations: CR, caloric restriction; eTRE, early time-restricted eating; ITRE, late time-restricted eating; TRE, time-restricted eating; mTRE, undefined beginning of time-restricted eating. The diamond at the base of the plot demonstrates the pooled effect estimates and confidence intervals from all RCTs included in the meta-analysis [7,11–16].

However, in both the eTRE and ITRE subgroups, TRE with CR was found to have a small and statistically non-significant effect on FM compared to the control group with CR (MD: -0.68 kg, 95% CI: -1.40 kg to 0.05 kg, p = 0.07; $l^2 = 0\%$ for eTRE and MD: -0.85 kg, 95% CI: -1.96 kg to 0.27 kg, p = 0.14; $l^2 = 0\%$ for ITRE). Because there was only one study [15] in the mTRE subgroup, no pooled analysis was possible (Figure 5a). Moreover, seven interventions included FFM as an outcome with 338 individuals (170 in the TRE with CR group and 168 in the control group with CR). There was no significant difference in FFM changes in the TRE with CR group vs. the control group with CR (MD: -0.22 kg, 95% CI: -0.68 kg to 0.25 kg, p = 0.36, $l^2 = 0\%$) (Figure 5b). The same was shown for the eTRE and mTRE subgroups (MD: -0.16 kg, 95% CI: -0.69 to 0.36 kg, p = 0.54, $l^2 = 0\%$ for eTRE and MD: -0.59 kg, 95% CI: -1.97 to 0.78 kg, p = 0.40, $l^2 = 0\%$ for mTRE). Since there was only one study in the ITRE subgroup, no pooled analysis was possible (Figure 5b).

Changes in WC were reported in five interventions (165 participants in the TRE with CR group, 166 in control group with CR). The results showed a statistically significantly greater reduction of WC in the TRE group with CR compared with the control group with CR (MD: -1.27 cm, 95% CI: -2.36 cm to -0.19 cm, p = 0.02, $l^2 = 0\%$) (Figure 6). In both the eTRE [11,16] and mTRE [14,15] groups, a small and statistically non-significant effect was observed regarding WC compared to the control group with CR (MD: -1.28 cm, 95% CI: -3.20 cm to 0.64 cm, p = 0.19, $l^2 = 0\%$ for eTRE and MD: -1.40 cm, 95% CI: -2.79 cm to -0.02 cm, p = 0.05, $l^2 = 0\%$ for mTRE). In the subgroup ITRE [11], pooled analysis was not possible (Figure 6).

	Exp	perimenta	al	Control				Mean difference	Mean difference	
study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI	
1.5.1 eTRE with CR										
He et al., 2022	-3.8	6.78	38	-2.4	8.16	55	12.7%	-1.40 [-4.45 , 1.65]		
Jamshed et al., 2022	-5.3	5.99	45	-4.1	5.99	45	19.3%	-1.20 [-3.68 , 1.28]		
Subtotal (95% CI)			83			100	31.9%	-1.28 [-3.20 , 0.64]	•	
Heterogeneity: Chi ² = 0.	.01, df = 1 (P = 0.92)	; l² = 0%							
Test for overall effect: Z	= 1.30 (P =	= 0.19)								
1.5.2 ITRE with CR										
He et al., 2022	-2.4	8.5	20	-2.4	8.16	55	6.4%	0.00 [-4.30 , 4.30]		
Subtotal (95% CI)			20			55	6.4%	0.00 [-4.30 , 4.30]		
Heterogeneity: Not appl	icable									
Test for overall effect: Z	= 0.00 (P =	= 1.00)								
1.5.3 mTRE with CR										
Kunduraci et al., 2020	-6.84	3.22	32	-5.15	3.16	33	49.0%	-1.69 [-3.24 , -0.14]		
Lin et al., 2022	-2.2	5.84	30	-1.9	6.5	33	12.7%	-0.30 [-3.35 , 2.75]		
Subtotal (95% CI)			62			66	61.7%	-1.40 [-2.79 , -0.02]	•	
Heterogeneity: Chi ² = 0.	.63, df = 1 (P = 0.43)	; l ² = 0%							
Test for overall effect: Z	= 1.99 (P =	= 0.05)								
Total (95% CI)			165			221	100.0%	-1.27 [-2.36 , -0.19]	•	
Heterogeneity: Chi ² = 1.	.02, df = 4 (P = 0.91)	; l ² = 0%						•	

Test for overall effect: Z = 2.30 (P = 0.02) Test for subgroup differences: Chi² = 0.37, df = 2 (P = 0.83), I² = 0%

> Figure 6. Effect of TRE with CR vs. CR on WC (in cm). Interventions divided in subgroups (eTRE, ITRE, mTRE). MD indicates the mean difference of change from TRE with CR vs. CR. The plotted points are the MDs, and the horizontal error bars represent the 95% confidence intervals. Abbreviations: CR, caloric restriction; eTRE, early time-restricted eating; ITRE, late time-restricted eating; TRE, time-restricted eating; mTRE, undefined beginning of time-restricted eating. The diamond at the base of the plot demonstrates the pooled effect estimates and confidence intervals from all RCTs included in the meta-analysis [11,14-16].

-10

TRE with CR [experimental]

-5

0

5

CR [control]

10

Five interventions provided data on SBP and DBP (159 participants in the TRE with CR group, 166 in control group with CR) [11,14–16]. The random effect for eTRE with CR subgroup showed a statistically significantly greater decrease in DBP (MD: -4.57 mmHg, 95% CI: -6.90 mmHg to -2.24 mmHg, p = 0.0001, $I^2 = 0\%$) (Figure 7a) compared to the control group with only CR [11,16]. On the other hand, there were no significant differences in SBP changes in the eTRE group [11,16] and not even in the mTRE [15,16] subgroup compared with the control group with CR (MD: -3.51 mmHg, 95% CI: -7.42 mmHg to 0.39 mmHg, p = 0.08, $l^2 = 0\%$ for eTRE and MD: 1.66 mmHg, 95% CI: -6.97 mmHg to 10.29 mmHg, p = 0.71, $I^2 = 75\%$ for mTRE) (Figure 7a). In the lTRE subgroup [11], no pooled analysis was possible for SBP and DBP (Figure 7a,b).

When performing the random-effect model, no significant difference in changes in SBP and DBP between the TRE group with CR vs. the CR group (MD: -0.36 mmHg, 95%CI: -4.65 mmHg to 3.84 mmHg, p = 0.87, $l^2 = 60\%$ for SBP and MD: -2.42 mmHg, 95% CI: -7.60 mmHg to 2.77 mmHg, p = 0.36, $I^2 = 95\%$ for DBP) was shown (Figure 7a,b).

	Exp	eriment	al		Control			Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.6.1 eTRE with CR									
He et al., 2022	-1	11.31	32	1	14.83	55	21.2%	-2.00 [-7.54 , 3.54]	
Jamshed et al., 2022	-8	13.31	45	-3	13.31	45	21.3%	-5.00 [-10.50 , 0.50]	
Subtotal (95% CI)			77			100	42.6%	-3.51 [-7.42 , 0.39]	•
Heterogeneity: Tau ² = 0	.00; Chi ² =	0.57, df =	= 1 (P = 0.	45); l ² = 0	%				-
Test for overall effect: Z	= 1.76 (P =	= 0.08)							
1.6.2 ITRE with CR									
He et al., 2022	3	13.42	20	1	14.82	55	17.2%	2.00 [-5.07 , 9.07]	_
Subtotal (95% CI)			20			55	17.2%	2.00 [-5.07 , 9.07]	
Heterogeneity: Not appl	licable								
Test for overall effect: Z	= 0.55 (P =	= 0.58)							
1.6.3 mTRE with CR									
Kunduraci et al., 2020	-7.35	9.42	32	-13	10.28	33	23.4%	5.65 [0.86 , 10.44]	
Lin et al., 2022	-3.1	10.65	30	0.1	18.07	33	16.8%	-3.20 [-10.45 , 4.05]	
Subtotal (95% CI)			62			66	40.2%	1.66 [-6.97 , 10.29]	
Heterogeneity: Tau ² = 2	9.34; Chi ² =	= 3.99, df	= 1 (P = (0.05); l ² = 1	75%				
Test for overall effect: Z	= 0.38 (P =	= 0.71)							
Total (95% CI)			159			221	100.0%	-0.36 [-4.56 , 3.84]	-
Heterogeneity: Tau ² = 1	3.66; Chi ² =	= 10.07, c	df = 4 (P =	0.04); l ² =	60%				T
Test for overall effect: Z	= 0.17 (P =	= 0.87)							-20 -10 0 10 20
Test for subgroup different	ences: Chi ²	= 2.46, 0	if = 2 (P =	0.29), l ² =	18.8%			TRE with CF	R [experimental] CR [control]
						(a)			
	Exp	eriment	al		Control			Mean difference	Mean difference

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.7.1 eTRE with CR									
He et al., 2022	-5	11.31	32	1	7.42	55	19.0%	-6.00 [-10.38 , -1.62]	
Jamshed et al., 2022	-5	6.66	45	-1	6.66	45	20.7%	-4.00 [-6.75 , -1.25]	
Subtotal (95% CI)			77			100	39.7%	-4.57 [-6.90 , -2.24]	•
Heterogeneity: Tau ² = 0	.00; Chi ² =	0.57, df =	= 1 (P = 0.	45); l ² = 0 ⁴	%				•
Test for overall effect: Z	= 3.84 (P =	= 0.0001)							
1.7.2 ITRE with CR									
He et al., 2022	3	8.94	20	1	7.42	55	19.0%	2.00 [-2.38 , 6.38]	- -
Subtotal (95% CI)			20			55	19.0%	2.00 [-2.38 , 6.38]	-
Heterogeneity: Not appl	licable								
Test for overall effect: Z	= 0.89 (P =	= 0.37)							
1.7.3 mTRE with CR									
Kunduraci et al., 2020	-4.75	0.91	32	-8.21	1.13	33	21.9%	3.46 [2.96 , 3.96]	
Lin et al., 2022	-4.8	7.48	30	3.4	9.06	33	19.3%	-8.20 [-12.29 , -4.11]	
Subtotal (95% CI)			62			66	41.3%	-2.19 [-13.61 , 9.23]	
Heterogeneity: Tau ² = 6	5.77; Chi ² =	= 30.78, c	if = 1 (P <	0.00001);	l ² = 97%				19.2076
Test for overall effect: Z	= 0.38 (P =	= 0.71)							
Total (95% CI)			159			221	100.0%	-2.42 [-7.60 , 2.77]	-
Heterogeneity: Tau ² = 3	1.89; Chi ² =	= 73.30, c	if = 4 (P <	0.00001);	l² = 95%				
Test for overall effect: Z	= 0.91 (P =	= 0.36)						-2	0 -10 0 10 3
Test for subgroup different	ences: Chi ²	= 6.75, d	f = 2 (P =	0.03), l ² =	70.4%			TRE with CR [experimental] CR [control]

(b)

Figure 7. Effect of TRE with CR vs. CR on changes in (**a**) SBP (in mmHg) and (**b**) DBP in (mmHg). Interventions were divided in subgroups (eTRE, ITRE, mTRE). MD indicates the mean difference of change from TRE with CR vs. CR. The plotted points are the MDs, and the horizontal error bars represent the 95% confidence intervals. Abbreviations: CR, caloric restriction; eTRE, early time-restricted eating; ITRE, late time-restricted eating; TRE, time-restricted eating; mTRE, undefined beginning of time-restricted eating. The diamond at the base of the plot demonstrates the pooled effect estimates and confidence intervals from all RCTs included in the meta-analysis [11,14–16].

3.2. Effects of TRE with CR vs. CR on Changes in Biochemical Parameters

Five interventions, including 131 participants in the TRE group with CR and 124 participants in the control group with CR, evaluated changes in blood levels of FG and lipid profile [7,14–16].

There were no significant differences in FG changes after the interventions between all TRE groups with CR and control groups with CR (MD: 0.14 mg/dL, 95% CI: -0.87 mg/dL to 1.15 mg/dL, p = 0.79, $l^2 = 35\%$) (Figure 8a). Similar results were obtained for the lipid profile. Indeed, the fixed-effect model showed no significant difference in TC changes (MD: 0.98 mg/dL, 95% CI: -2.19 mg/dL to 4.15 mg/dL, p = 0.54, $l^2 = 0\%$) (Figure 8b), changes in HDL (MD: 1.71 mg/dL, 95% CI: -0.22 mg/dL to 3.65 mg/dL, p = 0.08, $l^2 = 0\%$) (Figure 8c), changes in LDL (MD: -0.77 mg/dL, 95% CI: -2.59 mg/dL to 1.05 mg/dL, p = 0.41, $l^2 = 0\%$) (Figure 8d), and changes in TG levels (MD: 2.26 mg/dL, 95% CI: -4.43 mg/dL to 8.96 mg/dL, p = 0.51, $l^2 = 0\%$) (Figure 8e) between all TRE groups with CR and the control groups with CR.

	Exp	periment	al	Control				Mean difference	Mean difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI		
1.8.1 eTRE with CR											
Jamshed et al., 2022	-8	13.31	45	-6	13.31	45	3.4%	-2.00 [-7.50 , 3.50]			
Queiroz et al., 2023	-4	1.97	13	-3	1.95	13	44.9%	-1.00 [-2.51 , 0.51]	-		
Subtotal (95% CI)			58			58	48.2%	-1.07 [-2.52 , 0.38]	•		
Heterogeneity: Chi ² = 0.	.12, df = 1 (P = 0.73); I ² = 0%								
Test for overall effect: Z	= 1.44 (P =	= 0.15)									
1.8.2 ITRE with CR											
Queiroz et al., 2023	-2	1.97	11	-3	1.95	13	41.1%	1.00 [-0.57 , 2.57]	-		
Subtotal (95% CI)			11			13	41.1%	1.00 [-0.57 , 2.57]	•		
Heterogeneity: Not appl	licable								. Second Se		
Test for overall effect: Z	= 1.24 (P =	= 0.21)									
1.8.3 mTRE with CR											
Kunduraci et al., 2020	-15.47	33.26	32	-13.12	24.64	33	0.5%	-2.35 [-16.61 , 11.91]			
Lin et al., 2022	4.3	6.07	30	1.8	6.76	33	10.2%	2.50 [-0.67 , 5.67]			
Subtotal (95% CI)			62			66	10.7%	2.27 [-0.82 , 5.36]	•		
Heterogeneity: Chi ² = 0.	.42, df = 1 (P = 0.52); I ^z = 0%								
Test for overall effect: Z	= 1.44 (P =	= 0.15)									
Total (95% CI)			131			137	100.0%	0.14 [-0.87 , 1.15]	•		
Heterogeneity: Chi ² = 6.	.18, df = 4 (P = 0.19); l ² = 35%	0							
Test for overall effect: Z	= 0.27 (P =	= 0.79)							-20 -10 0 10 20		
Test for subgroup different	ences: Chi ²	= 5.63, 0	if = 2 (P =	0.06), I ² =	64.5%			TRE with CF	R [experimental] CR [control]		

(a)

Figure 8. Cont.

	Exp	erimenta	al		Control			Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.9.1 eTRE with CR									
Jamshed et al., 2022	-9	39.94	45	-15	39.94	45	3.7%	6.00 [-10.50 , 22.50]	
Queiroz et al., 2023	-12	16.55	13	-25	33.1	13	2.5%	13.00 [-7.12 , 33.12]	
Subtotal (95% CI)			58			58	6.2%	8.82 [-3.94 , 21.57]	-
Heterogeneity: Chi ² = 0.	28, df = 1 (P = 0.60)	; l ² = 0%						
Test for overall effect: Z	= 1.35 (P =	= 0.18)							
1.9.2 ITRE with CR									
Queiroz et al., 2023	-13	29.03	11	-25	33.1	13	1.6%	12.00 [-12.86 , 36.86]	
Subtotal (95% CI)			11			13	1.6%	12.00 [-12.86 , 36.86]	
Heterogeneity: Not appl	icable								
Test for overall effect: Z	= 0.95 (P =	= 0.34)							
1.9.3 mTRE with CR									
Kunduraci et al., 2020	-29.32	8.14	32	-29.36	5.74	33	85.2%	0.04 [-3.39 , 3.47]	
Lin et al., 2022	3.1	27.4	30	0.1	20.27	33	7.0%	3.00 [-9.00 , 15.00]	_ _
Subtotal (95% CI)			62			66	92.2%	0.26 [-3.04 , 3.57]	+
Heterogeneity: Chi ² = 0.	22, df = 1 (P = 0.64)	; l ² = 0%						
Test for overall effect: Z	= 0.16 (P =	= 0.88)							
Total (95% CI)			131			137	100.0%	0.98 [-2.19 , 4.15]	•
Heterogeneity: Chi ² = 2.	.88, df = 4 (P = 0.58)	; l ² = 0%						
Test for overall effect: Z	= 0.61 (P =	= 0.54)						-50	-25 0 25 50
Test for subgroup different	ences: Chi ²	= 2.38, d	f = 2 (P =	0.30), l ² =	16.1%			TRE with CR [ex	(perimental] CR [control]
						(b)			

	Experimental			Control				Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.10.1 eTRE with CR									
Jamshed et al., 2022	-4	6.66	45	-4	13.31	45	19.8%	0.00 [-4.35 , 4.35]	
Queiroz et al., 2023	-3	4.97	13	-7	5.79	13	21.8%	4.00 [-0.15 , 8.15]	
Subtotal (95% CI)			58			58	41.6%	2.09 [-0.91 , 5.10]	•
Heterogeneity: Chi ² = 1	.70, df = 1	(P = 0.19)	; l ² = 41%	6					•
Test for overall effect: Z	= 1.37 (P =	= 0.17)							
1.10.2 ITRE with CR									
Queiroz et al., 2023	-5	6.7	11	-7	5.79	13	14.7%	2.00 [-3.06 , 7.06]	
Subtotal (95% CI)			11			13	14.7%	2.00 [-3.06 , 7.06]	-
Heterogeneity: Not app	licable								
Test for overall effect: Z	= 0.78 (P =	= 0.44)							
1.10.3 mTRE with CR									
Kunduraci et al., 2020	0.53	7.1	32	-0.38	8.85	33	24.7%	0.91 [-2.98 , 4.80]	
Lin et al., 2022	1.5	9.91	30	-0.2	7.84	33	19.0%	1.70 [-2.74 , 6.14]	
Subtotal (95% CI)			62			66	43.7%	1.25 [-1.68 , 4.18]	•
Heterogeneity: Chi ² = 0	.07, df = 1	(P = 0.79)	; l ² = 0%						
Test for overall effect: Z	= 0.84 (P =	= 0.40)							
Total (95% CI)			131			137	100.0%	1.71 [-0.22 , 3.65]	•
Heterogeneity: Chi ² = 1	.94, df = 4	(P = 0.75)	; l ² = 0%						
Test for overall effect: Z	= 1.73 (P =	= 0.08)						-20	-10 0 10
Test for subgroup different	ences: Chi ²	= 0.17, d	lf = 2 (P =	0.92), I² =	0%			TRE with CR [e	xperimental] CR [control]

(c)

Figure 8. Cont.

	Eve	eriment	al		Control			Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
1.11.1 eTRE with CR	-	00.00	45		00.00		0.70/	4001700 45001	
Jamshed et al., 2022	-5	26.63	45	-9	26.63	45	2.7%	4.00 [-7.00 , 15.00]	
Queiroz et al., 2023	-8	13.24	13	-14	25.65	13	1.3%	6.00 [-9.69 , 21.69]	
Subtotal (95% CI)		in de ste	58			58	4.1%	4.66 [-4.35 , 13.67]	•
Heterogeneity: Chi ² = 0.	.04, df = 1 ((P = 0.84)	; $ ^2 = 0\%$						
Test for overall effect: Z	= 1.01 (P =	= 0.31)							
1.11.2 ITRE with CR									
Queiroz et al., 2023	-7	24.82	11	-14	25.65	13	0.8%	7.00 [-13.24 , 27.24]	
Subtotal (95% CI)			11			13	0.8%	7.00 [-13.24 , 27.24]	
Heterogeneity: Not appl	icable								
Test for overall effect: Z	= 0.68 (P =	= 0.50)							
1.11.3 mTRF with CR									
Kunduraci et al 2020	-17	3 96	32	-15 07	3.84	33	92 0%	-1 03 [-2 93 0 87]	_
in et al 2022	-1.5	21 7	30	0.7	19.74	33	3 1%	-2 20 [-12 /8 8 08]	-
Subtotal (95% CI)	-1.5	21.7	50	0.7	15.74	33	05 1%	-2.20 [-12.40, 0.00]	
	05 df = 1	D = 0.92	· 12 = 0%			00	55.1%	-1.07 [-2.85, 0.60]	٩
Test for everall effects 7	= 1 12 /P	- 0.03)	, 1 0%						
lest for overall effect: Z	= 1.12 (P =	= 0.26)							
fotal (95% CI)			131			137	100.0%	-0.77 [-2.59 , 1.05]	•
Heterogeneity: Chi ² = 2.	15, df = 4	(P = 0.71)	; l ² = 0%						
Test for overall effect: Z	= 0.83 (P =	= 0.41)						-5	0 -25 0 25
Test for subgroup different	ences: Chi ²	= 2.06, d	f = 2 (P =	: 0.36), I ²	= 2.9%			TRE with CR [experimental] CR [control]
						(d)			
	Ex	perimenta	al		Control			Mean difference	Mean difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.12.1 eTRE with CR									
Jamshed et al., 2022	-3	59.91	45	-9	59.91	45	7.3%	6.00 [-18.75 , 30.75]	
Queiroz et al., 2023	-6	14.9	13	-14	33.44	13	11.3%	8.00 [-11.90 , 27.90]	
Subtotal (95% CI)			58			58	18.7%	7.21 [-8.30 . 22.72]	
Heterogeneity: Chi ² = 0	.02. df = 1	(P = 0.90)	$ ^2 = 0\%$					•	
Test for overall effect: Z	= 0.91 (P	= 0.36)							
1.12.2 ITRE with CR									
Queiroz et al 2023	-1	20.84	11	-14	33 44	13	9.3%	13 00 [-8 96 34 96]	a survey and
Subtotal (95% CI)	-1	20.04	11	- 14	55.44	13	9.3%	13 00 [-8 96 34 96]	
Heterogeneity: Not ann	licable					13	0.0 %	10.00 [-0.00 , 34.00]	
Test for overall effect: Z	= 1.16 (P =	= 0.25)							
1.12.3 mTRE with CR									
Kunduraci et al., 2020	-41.84	16.35	32	-40	21.73	33	51.5%	-1.84 [-11.17 , 7.49]	
Lin et al., 2022	-7.6	28.33	30	-10.8	31.57	33	20.5%	3.20 [-11.59 , 17.99]	
Subtotal (95% CI)			62			66	72.0%	-0.41 [-8.30 , 7.49]	+
Heterogeneity: Chi ² = 0	.32, df = 1	(P = 0.57)	; l² = 0%						
Test for overall effect: Z	= 0.10 (P =	= 0.92)							

Total (95% CI) 131 Heterogeneity: Chi² = 2.08, df = 4 (P = 0.72); l² = 0% Test for overall effect: Z = 0.66 (P = 0.51)

Test for subgroup differences: $Chi^2 = 1.75$, df = 2 (P = 0.42), $I^2 = 0\%$

(e)

137 100.0%

Figure 8. Effects of TRE with CR vs. CR on changes in (a) FG (in mg/dL), (b) TC (in mg/dL), (c) HDL cholesterol (in mg/dL), (d) LDL cholesterol (in mg/dL), and (e) TG (in mg/dL). Interventions were divided in subgroups (eTRE, ITRE, mTRE). MD indicates the mean difference of change from TRE with CR vs. CR. The plotted points are the MDs, and the horizontal error bars represent the 95% confidence intervals. Abbreviations: CR, caloric restriction; eTRE, early time-restricted eating; ITRE, late time-restricted eating; TRE, time-restricted eating; mTRE, undefined beginning of time-restricted eating. The diamond at the base of the plot demonstrates the pooled effect estimates and confidence intervals from all RCTs included in the meta-analysis [7,14–16].

2.26 [-4.43 . 8.96]

-50 -25 TRE with CR [experimental]

25

CR [control]

50

3.3. Certainty of the Evidence

Table 2 presents the GRADE assessment results. Among 11 outcomes analyzed, SBP and DBP were classified as very low quality, and the other nine (BW, BM, FFM, WC, FG, TC, HDL, LDL, TG) were graded as low.

4. Discussion

The aim of the present meta-analysis was to evaluate the anthropometric and cardiometabolic effects of TRE with CR vs. CR in overweight and obese adults and to determine which subgroup of TRE is the most effective in combination with CR.

Our meta-analysis included seven studies with nine interventions and 458 participants. The interventions lasted 8 to 14 weeks and included 14 to 16 h of daily fasting with 8 to 10 h eating periods. The control group received CR and in one case a low-carbohydrate diet with no restricted eating window. Outcomes measured included BW, FM, FFM, WC, DBP, SBP, FG, TC, HDL, LDL, and TG. Two studies were categorized as having a high risk of bias, whereas others raised some concerns. The GRADE evaluation rated two of the eleven outcomes from the current study as very low quality, and the remaining nine where classified as low quality.

The main results of our meta-analysis highlight the additive effect of TRE in the presence of CR on anthropometric parameters, especially on BW, FM loss, and WC reduction, compared with CR alone. However, we found no additional impact of TRE in combination with CR on serum biochemical parameters when compared with CR. It is important to note that the analysis of biochemical parameters showed low heterogeneity ($I^2 < 35\%$), indicating consistent results across study participants and variables. In contrast, heterogeneity was higher in the analysis of blood pressure with I^2 values of 60% (SBP) and 95% (DBP), indicating considerable inconsistency or heterogeneity between studies, which may be caused by study design, population characteristics, interventions, or other factors contributing to the observed heterogeneity.

Thus, the main finding from this meta-analysis is that the improvement in biochemical parameters primarily results from CR, while improvements in anthropometric parameters are further enhanced by TRE.

Our findings are consistent with previous studies showing that TRE in combination with CR can significantly affect body composition. Pooled analysis showed a statistically significant and superior effect of the TRE group with CR in terms of BW reduction (average -2.11 kg), FM loss (average -0.75 kg), and WC reduction (average -1.27 cm) compared to the control CR group. Importantly, the aim of dietary strategies is always to reduce BW by maintaining FFM. Indeed, it is important to maintain FFM during weight loss because of its integral role in metabolic rate regulation, preservation of skeletal integrity, and maintenance of functional capacity. In our meta-analysis, the additional reduction in BW in the TRE group with CR did not result in additional reduction in FFM; the mean differences in FFM were not statistically significant between the TRE with CR group and the CR group. The results of a previous meta-analysis are in agreement with our results as they also showed a statistically significant difference regarding BW and FM loss without statistically significant effects on FFM in the TRE with CR vs. CR groups [20]. In individuals with obesity, weight loss is one of the most important strategies to improve health outcomes and prevent or eliminate obesity-related health complications. Data from clinical trials have convincingly shown that a 5% weight loss is considered clinically important [21], and sustained weight loss of 2–5% has shown significant benefits for cardiovascular risk factors [22,23]. However, there is a continuum of clinically important weight loss that varies between individuals and is dependent on comorbidities/complications [21].

Furthermore, the choice of daily eating time appears to have an impact on BW loss and DBP reduction. In our meta-analysis, eTRE with CR and ITRE with CR showed a statistically significant effect on BW vs. CR. In addition, eTRE with CR showed a greater effect on BW than ITRE with CR (eTRE -2.43 kg vs. ITRE -1.43 kg). There was also a statistically significantly greater decrease in DBP in the eTRE with CR subgroup compared to the CR group. A meta-analysis, which also included clinical studies where participants in TRE group ate ad libitum, showed a greater trend of BW reduction in eTRE than ITRE, although the changes in BW were not statistically significant between groups. In the same meta-analysis, the results indicated that eTRE was associated with a higher decrease in DBP compared with non-TRE [24].

One explanation for the anthropometric changes in the TRE groups may be related to the utilization of fatty acids and ketones for energy, because after 6–8 h of fasting, a switch from fat storage to fat utilization occurs [25]. The important consideration related to eTRE vs. ITRE regarding BW loss might be related to the internal circadian clock [26]. Namely, a regulated circadian clock daily regulates the secretion of several hormones and induces a balance between catabolic and anabolic processes. Hormones that are important for regulating metabolism reach their peak secretion in the morning during the active phase. For example, adiponectin, which stimulates fatty acid oxidation and glycolysis and inhibits fat accumulation, is produced between 8 am and 4 pm. Such a mechanism may indicate that the timing for food intake is better in the morning than later in the afternoon [27].

In agreement with previous studies [28–30], the main finding of the present metaanalysis is that the improvement in biochemical parameters is mainly caused by CR. TRE with CR had no significant effects on the changes of FG, TC, LDL cholesterol, HDL cholesterol, and TG when compared with CR.

When comparing TRE ad libitum with non-TRE ad libitum, previous studies showed a significant effect of TRE on lowering FG [24,31], whereas the effects of TRE on the lipid profile are less consistent. Some studies have shown no or negative effects on lipid profile [16,20], while others have indicated positive changes in certain lipid profiles [32,33]. A meta-analysis by Liu showed that neither eTRE nor ITRE had a significant effect on lipid profiles in obese or overweight individuals with normal lipid profiles [24]. In the present meta-analysis, serum TC levels decreased more, although not significantly, in the CR group, suggesting a negative effect of TRE in combination with CR on lowering TC levels.

The variability in the effects of TRE on lipid profiles observed in the different studies can be explained by several factors. Participant characteristics are crucial, as some studies focused on overweight or obese individuals with normal lipid profiles, whereas other studies targeted individuals with pre-existing dyslipidemia or other metabolic diseases. Participants' baseline lipid levels can significantly affect the outcomes [24,32]. Another factor is the differences in TRE interventions that determine the duration of fasting, timing of meals, and overall CR [34]. These differences in the study design can lead to different effects on fat metabolism. For example, the duration of fasting may affect the body's response to fat metabolism differently. Individual differences in genetic predisposition and metabolic response also influence outcomes [35]. Furthermore, it is also important to consider the limitations of the studies themselves [20,36,37]. We acknowledge that the present study also has some limitations. The main limitation of the present meta-analysis is the inclusion of a study comparing TRE with a low-carbohydrate diet compared with a low-carbohydrate diet, in which we assumed that spontaneous caloric restriction occurred. However, our results did not differ depending on whether the study was included or not. In addition, the study was categorized into eTRE and ITRE, which facilitated the comparison of subgroups. And finally, the quality of the study results was categorized as low or very low according to the GRADE tool. This was primarily attributed to the risk of bias caused mainly by the nature of the behavioral intervention, as it was not possible to blind participants due to the different time frames of fasting and eating. Secondly, it can be attributed to inconsistency, due to the high heterogeneity of some results (e.g., SBP and DBP), and finally it can be attributed to variability in energy restriction protocols. However, the main strength of our meta-analysis compared to other meta-analyses on this topic is that we used only homogeneous studies that included asymptomatic individuals who were overweight or obese with or without components of metabolic syndrome but without chronic diseases and in which fasting time ranged from 14-16 h and study duration was 2–4 months. This approach allowed us to minimize the large heterogeneity of the

results, knowing that, for example, the response of individuals with diabetes or some other disorders may be different [20,36,38,39]. In addition, there is also a major problem in interpreting the results more accurately due to the different lengths of the time windows for eating and fasting (8:16–12:12) and, consequently, the small difference between the intervention group and the control group (2 h) [37]. Moreover, the length of studies in other meta-analyses varied from 45 days to 12 months [20,37]. Therefore, longitudinal studies may introduce bias into the results due to non-adherence to the time window and higher attrition. And finally, we would also like to point out that we performed subgroup analyses for eTRE, mTRE, and ITRE. These three subgroups were compared in terms of all anthropometric and biochemical parameters, which has been deficient in other meta-analyses [20,36,37].

5. Conclusions

Overall, based on these meta-analysis results, it appears that TRE with CR significantly improves some anthropometric outcomes compared with CR, especially BW, FM, and WC. Moreover, within the eTRE subgroup with CR statistically significant improvements were also shown for DBP. On the other hand, TRE with CR did not lead to significant improvements or differences in FFM, SBP, FG, TC, HDL and LDL cholesterol, and TC compared to the CR group. It is important to consider the limitations of the included studies, such as sample size, duration, and possible differences in study design, which could affect the results presented.

As our results suggest that the improvement in biochemical parameters is mainly caused by CR, while improvements in anthropometric parameters are further enhanced by TRE, TRE with CR could be recommended for individuals with BMI > 25 kg/m^2 and for those who want to lose BW and FM in a short period of time.

However, further studies are needed to investigate the long-term effects of TRE with CR on anthropometric and metabolic parameters to better understand the potential benefits or limitations of this dietary intervention.

Author Contributions: Conceptualization, T.Č., B.H., Z.J.P. and A.P.; methodology, T.Č., B.H., Z.J.P. and A.P.; formal analysis, T.Č, B.H., Z.J.P. and A.P.; investigation, T.Č, B.H., Z.J.P. and A.P.; writing—original draft preparation, T.Č and B.H.; writing—review and editing, T.Č., B.H., Z.J.P. and A.P.; supervision, Z.J.P. and A.P.; project administration, Z.J.P. and A.P.; funding acquisition, A.P. and Z.J.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was financially supported by the Slovenian Research and Innovation Agency (Programme P1-0386, Infrastructure Programme I0-0035 and grant number 56962 for junior researcher Tanja Črešnovar).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A. Search Strategy for Each Database

1. Pubmed

(((((((time restricted eating[Title/Abstract])) OR (time restricted feeding[Title/Abstract])) OR (time restricted diet[Title/Abstract])) AND (calorie restriction[Title/Abstract])) OR (energy restriction[Title/Abstract])) OR (caloric restriction[Title/Abstract])) AND (overweight[MeSH Terms])) OR (obesity[MeSH Terms])) OR (metabolic syndrome[MeSH Terms])) OR (weight loss[MeSH Terms])

2. Web of Science

Results for TIME RESTRICTED EATING (Title) OR TIME RESTRICTED FEEDING (Title) OR TIME RESTRICTED DIET (Title) AND CALORIC RESTRICTION (Title) OR CALORIE RESTRICTION (Title) OR ENERGY RESTRICTION (Title) and Open Access and 2023 or 2022 or 2021 or 2020 or 2019 or 2010 or 2011 or 2012 or 2013 or 2014 or 2015 or 2016 or 2017 or 2018 (Publication Years) and Article (Domcument Types).

3. Cochrane library

#1 (Time restricted feeding): ti, ab, kw #2 (Time restricted eating): ti, ab, kw #3 (Time restricted diet); ti, ab, kw #4 #1 or #2 or #3 #5 (Calorie restriction): ti, ab, kw #6 (Energy restriction): ti, ab, kw #7 (Caloric restriction): ti, ab, kw #8 #5 or #6 or #7 MeSH descriptor: #9 (overweight) #10 (obesity) #11 (obese) #12 (metabolic syndrome) #13 (weight loss) #14 (weight reduction) #15 #9 or #10 or #11 or #12 or #13 or #14 #16 #4 and #8 and #15 4.

Embase

Time restricted eating OR time restricted feeding OR time restricted eating OR time restricted diet OR time restricted feeding AND calorie restriction OR caloric restriction OR energy restriction AND weight loss OR overweight OR obesity OR metabolic syndrome.

Appendix B.

Table A1. 2020 Checklist.

Section and Topic	Item #	Checklist Item	Location Where Item Is Reported
		TITLE	
Title	1	Identify the report as a systematic review.	Title page
		ABSTRACT	
Abstract	2	See the PRISMA 2020 for abstract checklist.	Title page
		INTRODUCTION	
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Section 1
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Section 1
		METHODS	
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Section 2.2
Information sources	6	Specify all databases, registers, websites, organisations, reference lists, and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Section 2.1
Search strategy	7	Present the full search strategies for all databases, registers, and websites, including any filters and limits used.	Section 2.1 and Appendix A
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved; whether they worked independently; and if applicable, details of automation tools used in the process.	Section 2.1

Section and Topic	Item #	Checklist Item	Location Where Item Is Reported
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report; whether they worked independently; any processes for obtaining or confirming data from study investigators; and if applicable, details of automation tools used in the process.	Section 2.3
Data items _	10 a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Section 2.2
	10 b	List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Sections 2.1 and 2.2
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used; how many reviewers assessed each study and whether they worked independently; and if applicable, details of automation tools used in the process.	Section 2.4
Effect measures	12	Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results.	Section 2.4
	13 a	Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Section 2.2 and Figure 1
	13 b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Section 2.4
	13 c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Section 2.4
	13 d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s) and method(s) to identify the presence and extent of statistical heterogeneity, as well as software package(s) used.	Sections 2.4 and 2.5
	13 e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression).	Section 2.5
	13 f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Section 2.4
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Figure 2
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Section 2.4 and Table 2
RESULTS			
Study selection	16 a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1
	16 b	Cite studies that might appear to meet the inclusion criteria but were excluded, and explain why they were excluded.	Figure 1
Study characteristics	17	Cite each included study and present its characteristics.	Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Figure 2
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots.	Figures 3–8

Table A1. Cont.

Section and Topic	Item #	Checklist Item	Location Where Item Is Reported				
Results of syntheses	20 a	For each synthesis, briefly summarize the characteristics and risk of bias among contributing studies.	Table 1				
	20 b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Section 3				
	20 c	Present results of all investigations of possible causes of heterogeneity among study results.	Section 3				
	20 d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Section 3				
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Figure 2				
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Table 2				
		DISCUSSION					
– Discussion _	23 a	Provide a general interpretation of the results in the context of other evidence.	Section 4				
	23 b	Discuss any limitations of the evidence included in the review.	Section 4				
	23 с	Discuss any limitations of the review processes used.	Section 4				
	23 d	Discuss implications of the results for practice, policy, and future research.	Section 4				
OTHER INFORMATION							
Registration and protocol	24 a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Section 2.1				
	24 b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Ν				
	24 c	Describe and explain any amendments to information provided at registration or in the protocol.	Ν				
Support	25	Describe sources of financial or non-financial support for the review, as well as the role of the funders or sponsors in the review.	Funding				
Competing interests	26	Declare any competing interests of the review authors.	Conflicts of Interest				
Availability of data, code, and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; and any other materials used in the review.	Ν				

Table A1. Cont.

References

- Lin, X.; Li, H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. *Front. Endocrinol.* 2021, 12, 706978. [CrossRef] [PubMed]
- Stefan, N.; Birkenfeld, A.L.; Schulze, M.B. Global Pandemics Interconnected—Obesity, Impaired Metabolic Health and COVID-19. Nat. Rev. Endocrinol. 2021, 17, 135–149. [CrossRef] [PubMed]
- 3. Alimoradi, Z.; Golboni, F.; Griffiths, M.D.; Broström, A.; Lin, C.Y.; Pakpour, A.H. Weight-Related Stigma and Psychological Distress: A Systematic Review and Meta-Analysis. *Clin. Nutr.* **2020**, *39*, 2001–2013. [CrossRef] [PubMed]
- 4. Blüher, M. Obesity: Global Epidemiology and Pathogenesis. Nat. Rev. Endocrinol. 2019, 15, 288–298. [CrossRef]
- Kim, J.Y. Optimal Diet Strategies for Weight Loss and Weight Loss Maintenance. J. Obes. Metab. Syndr. 2021, 30, 20–31. [CrossRef]
 Rynders, C.A.; Thomas, E.A.; Zaman, A.; Pan, Z.; Catenacci, V.A.; Melanson, E.L. Effectiveness of Intermittent Fasting and
- Time-Restricted Feeding Compared to Continuous Energy Restriction for Weight Loss. Nutrients 2019, 11, 2442. [CrossRef]
- Queiroz, J.D.N.; MacEdo, R.C.O.; Dos Santos, G.C.; Munhoz, S.V.; MacHado, C.L.F.; De Menezes, R.L.; Menzem, E.N.; Moritz, C.E.J.; Pinto, R.S.; Tinsley, G.M.; et al. Cardiometabolic Effects of Early v. Delayed Time-Restricted Eating plus Energetic Restriction in Adults with Overweight and Obesity: An Exploratory Randomised Clinical Trial. *Br. J. Nutr.* 2023, *129*, 637–649. [CrossRef]
- 8. Xie, Z.; Sun, Y.; Ye, Y.; Hu, D.; Zhang, H.; He, Z.; Zhao, H.; Yang, H.; Mao, Y. Randomized Controlled Trial for Time-Restricted Eating in Healthy Volunteers without Obesity. *Nat. Commun.* **2022**, *13*, 1003. [CrossRef]

- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. *Int. J. Surg.* 2021, 88, 105906. [CrossRef]
- Methley, A.M.; Campbell, S.; Chew-Graham, C.; McNally, R.; Cheraghi-Sohi, S. PICO, PICOS and SPIDER: A Comparison Study of Specificity and Sensitivity in Three Search Tools for Qualitative Systematic Reviews. *BMC Health Serv. Res.* 2014, 14, 579. [CrossRef]
- He, M.; Wang, J.; Liang, Q.; Li, M.; Guo, H.; Wang, Y.; Deji, C.; Sui, J.; Wang, Y.W.; Liu, Y.; et al. Time-Restricted Eating with or without Low-Carbohydrate Diet Reduces Visceral Fat and Improves Metabolic Syndrome: A Randomized Trial. *Cell Rep. Med.* 2022, 3, 100777. [CrossRef] [PubMed]
- Thomas, E.A.; Zaman, A.; Sloggett, K.J.; Steinke, S.; Grau, L.; Catenacci, V.A.; Cornier, M.; Rynders, C.A. Early Time-restricted Eating Compared with Daily Caloric Restriction: A Randomized Trial in Adults with Obesity. *Obesity* 2022, 30, 1027–1038. [CrossRef]
- Steger, F.L.; Jamshed, H.; Bryan, D.R.; Richman, J.S.; Warriner, A.H.; Hanick, C.J.; Martin, C.K.; Salvy, S.J.; Peterson, C.M. Early Time-Restricted Eating Affects Weight, Metabolic Health, Mood, and Sleep in Adherent Completers: A Secondary Analysis. *Obesity* 2023, *31*, 96–107. [CrossRef] [PubMed]
- Lin, Y.J.; Wang, Y.T.; Chan, L.C.; Chu, N.F. Effect of Time-Restricted Feeding on Body Composition and Cardio-Metabolic Risk in Middle-Aged Women in Taiwan. *Nutrition* 2022, 93, 111504. [CrossRef] [PubMed]
- 15. Kunduraci, Y.E.; Ozbek, H. Does the Energy Restriction Intermittent Fasting Diet Alleviate Metabolic Syndrome Biomarkers? A Randomized Controlled Trial. *Nutrients* **2020**, *12*, 3213. [CrossRef]
- Jamshed, H.; Steger, F.L.; Bryan, D.R.; Richman, J.S.; Warriner, A.H.; Hanick, C.J.; Martin, C.K.; Salvy, S.J.; Peterson, C.M. Effectiveness of Early Time-Restricted Eating for Weight Loss, Fat Loss, and Cardiometabolic Health in Adults with Obesity: A Randomized Clinical Trial. *JAMA Intern. Med.* 2022, 182, 953–962. [CrossRef]
- 17. Higgins, J.P.T.; Altman, D.G.; Gotzsche, P.C.; Juni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.C. The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials. *BMJ* **2011**, *343*, d5928. [CrossRef]
- Guyatt, G.; Oxman, A.D.; Akl, E.A.; Kunz, R.; Vist, G.; Brozek, J.; Norris, S.; Falck-Ytter, Y.; Glasziou, P.; deBeer, H. GRADE Guidelines: 1. Introduction—GRADE Evidence Profiles and Summary of Findings Tables. J. Clin. Epidemiol. 2011, 64, 383–394. [CrossRef]
- 19. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. (Eds.) *Cochrane Handbook for Systematic Reviews of Interventions*; Wiley: Hoboken, NJ, USA, 2019; ISBN 9781119536628.
- Huang, L.; Chen, Y.; Wen, S.; Lu, D.; Shen, X.; Deng, H.; Xu, L. Is Time-Restricted Eating (8/16) Beneficial for Body Weight and Metabolism of Obese and Overweight Adults? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Food Sci. Nutr.* 2023, *11*, 1187–1200. [CrossRef]
- Horn, D.B.; Almandoz, J.P.; Look, M. What Is Clinically Relevant Weight Loss for Your Patients and How Can It Be Achieved? A Narrative Review. *Postgrad. Med.* 2022, 134, 359–375. [CrossRef]
- 22. Ryan, D.H.; Yockey, S.R. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. *Curr. Obes. Rep.* 2017, *6*, 187–194. [CrossRef] [PubMed]
- Wing, R.R.; Lang, W.; Wadden, T.A.; Safford, M.; Knowler, W.C.; Bertoni, A.G.; Hill, J.O.; Brancati, F.L.; Peters, A.; Wagenknecht, L. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes. *Diabetes Care* 2011, 34, 1481–1486. [CrossRef] [PubMed]
- Liu, J.; Yi, P.; Liu, F. The Effect of Early Time-Restricted Eating vs. Later Time-Restricted Eating on 2 Weight Loss and Metabolic Health: A Network Meta-Analysis of Randomized Controlled Trials Keywords. J. Clin. Endocrinol. Metab. 2023, 108, 1824–1834. [CrossRef] [PubMed]
- 25. Dong, T.A.; Sandesara, P.B.; Dhindsa, D.S.; Mehta, A.; Arneson, L.C.; Dollar, A.L.; Taub, P.R.; Sperling, L.S. Intermittent Fasting: A Heart Healthy Dietary Pattern? *Am. J. Med.* 2020, 133, 901–907. [CrossRef] [PubMed]
- Paoli, A.; Tinsley, G.; Bianco, A.; Moro, T. The Influence of Meal Frequency and Timing on Health in Humans: The Role of Fasting. *Nutrients* 2019, 11, 719. [CrossRef]
- 27. Charlot, A.; Hutt, F.; Sabatier, E.; Zoll, J. Beneficial Effects of Early Time-Restricted Feeding on Metabolic Diseases: Importance of Aligning Food Habits with the Circadian Clock. *Nutrients* **2021**, *13*, 1405. [CrossRef] [PubMed]
- Hołowko, J.; Michalczyk, M.M.; Zajac, A.; Czerwińska-Rogowska, M.; Ryterska, K.; Banaszczak, M.; Jakubczyk, K.; Stachowska, E. Six Weeks of Calorie Restriction Improves Body Composition and Lipid Profile in Obese and Overweight Former Athletes. *Nutrients* 2019, *11*, 1461. [CrossRef] [PubMed]
- Huffman, K.M.; Parker, D.C.; Bhapkar, M.; Racette, S.B.; Martin, C.K.; Redman, L.M.; Das, S.K.; Connelly, M.A.; Pieper, C.F.; Orenduff, M.; et al. Calorie Restriction Improves Lipid-Related Emerging Cardiometabolic Risk Factors in Healthy Adults without Obesity: Distinct Influences of BMI and Sex from CALERIE TM a Multicentre, Phase 2, Randomised Controlled Trial. *EClinicalMedicine* 2022, 43, 101261. [CrossRef]
- Soare, A.; Weiss, E.P.; Pozzilli, P. Benefits of Caloric Restriction for Cardiometabolic Health, Including Type 2 Diabetes Mellitus Risk. *Diabetes Metab. Res. Rev.* 2014, 30, 41–47. [CrossRef]
- 31. Liu, L.; Chen, W.; Wu, D.; Hu, F. Metabolic Efficacy of Time-Restricted Eating in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Endocrinol. Metab. 2022, 107, 3428–3441. [CrossRef]

- Meng, H.; Zhu, L.; Kord-Varkaneh, H.O.; Santos, H.; Tinsley, G.M.; Fu, P. Effects of Intermittent Fasting and Energy-Restricted Diets on Lipid Profile: A Systematic Review and Meta-Analysis. *Nutrition* 2020, 77, 110801. [CrossRef] [PubMed]
- Santos, H.O.; Macedo, R.C.O. Impact of Intermittent Fasting on the Lipid Profile: Assessment Associated with Diet and Weight Loss. Clin. Nutr. ESPEN 2018, 24, 14–21. [CrossRef]
- Pellegrini, M.; Cioffi, I.; Evangelista, A.; Ponzo, V.; Goitre, I.; Ciccone, G.; Ghigo, E.; Bo, S. Effects of Time-Restricted Feeding on Body Weight and Metabolism. A Systematic Review and Meta-Analysis. *Rev. Endocr. Metab. Disord.* 2020, 21, 17–33. [CrossRef] [PubMed]
- 35. Ordovas, J.M. Genetic Influences on Blood Lipids and Cardiovascular Disease Risk: Tools for Primary Prevention. *Proc. Am. J. Clin. Nutr.* **2009**, *89*, 1509S–1517S. [CrossRef]
- Sun, J.C.; Tan, Z.T.; He, C.J.; Hu, H.L.; Zhai, C.L.; Qian, G. Time-Restricted Eating with Calorie Restriction on Weight Loss and Cardiometabolic Risk: A Systematic Review and Meta-Analysis. *Eur. J. Clin. Nutr.* 2023, 7, 1014–1025. [CrossRef] [PubMed]
- Chen, W.; Liu, X.; Bao, L.; Yang, P.; Zhou, H. Health Effects of the Time-Restricted Eating in Adults with Obesity: A Systematic Review and Meta-Analysis. Front. Nutr. 2023, 10, 1079250. [CrossRef]
- Turner, L.; Charrouf, R.; Martínez-Vizcaíno, V.; Hutchison, A.; Heilbronn, L.K.; Fernández-Rodríguez, R. The Effects of Time-Restricted Eating versus Habitual Diet on Inflammatory Cytokines and Adipokines in the General Adult Population: A Systematic Review with Meta-Analysis. Am. J. Clin. Nutr. 2023, in press. [CrossRef]
- Schroor, M.M.; Joris, P.J.; Plat, J.; Mensink, R.P. Effects of Intermittent Energy Restriction Compared with Those of Continuous Energy Restriction on Body Composition and Cardiometabolic Risk Markers—A Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults. *Adv. Nutr.* 2023, *in press.* [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.